Crystalline forms of a ryanodine receptor modulator and uses thereof
US12076326B2 · kind B2 · utility
0Cited by
7References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 17, 2022 |
| Grant date | Sep 3, 2024 |
| Priority date | — |
| Expiry date | Nov 9, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/554
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to crystalline forms of the compound 4-[(7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)yl)methyl]benzoic acid hemifumarate, pharmaceutical compositions comprising these compounds and uses thereof to treat diseases and conditions associated with Ryanodine Receptor (RyR) dysfunction, in particular cardiac and musculoskeletal disorders and diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.